Solid dispersion of famotidine: Factorially designed capsule formulation and in vivo evaluation of antiulcer activity

Saudi Pharmaceutical Journal

Volumn 12, Issue 4, 2004, Pages 119-129

  Geneidi, A S ^a   ElShamy, A H ^a   Awad, G A S ^a   Hassan, A O K ^a   ElDemerdash, E ^a  

^a Ain Shams University   (Egypt)

Author keywords

Anti ulcer activity; Capsules; Enhancement of dissolution; Factorial design; Famotidine; Polyethylene glycol; Solid dispersions

Indexed keywords

AEROSIL; ANTIULCER AGENT; CROSCARMELLOSE SODIUM; DILUENT; EXCIPIENT; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; LACTOSE; LUBRICATING AGENT; MACROGOL 4000; MACROGOL 6000; MAGNESIUM STEARATE; MANNITOL; MICROCRYSTALLINE CELLULOSE; POTASSIUM DIHYDROGEN PHOSPHATE; STARCH; STARCH GLYCOLATE SODIUM; TALC;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; FLOW; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SOLID DISPERSION; SPECTROPHOTOMETRY; STOMACH ULCER; X RAY DIFFRACTION;

EID: 11144321455     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. 2 blockers; Lancet; 1983; 2:1078.
2. 2 receptor blocker, in plasma and urine; J. Chromatogr.; 1988; 338:438-443.
3. Chiou, W. L.; Riegelman, S.; Pharmaceutical applications of solid dispersion systems; J. Pharm. Sci.; 1971; 60:1281-1302.
4. Ford, J. L.; The current status of solid dispersions; Pharm. Acta Helv.; 1986; 61:69-88.
5. Swarbrick J. and Boylan, C.; Encyclopedia of pharmaceutical technology; vol 2; (1990); Marcel Dekker, Inc.;262-263.
6. 4 factorial design; Drug Dev. Ind. Pharm.; 1996; 22(7):623-630.
7. Elkheshen, A. S.; Abdel-Gawad; N. A.; Badawi, A., A.; Factorial design and computer optimisation of a reconstitutable suspension of erythromycin ethyl succinate »; Die Pharm. Ind.; 1997; 59(5):439-443
8. Newton, J. M. and Razzo, F. N.; The influence of additives on the in vitro release of drugs from hard gelatin capsules; J. Pharm. Pharmacol.; 1974; 26; Suppl.:30-6
9. Stewart, A. G.; Grant, G. W.; Newton, J. M.; The release of a model low-dose drug (riboflavine) from hard gelatin capsule formulations; J. Pharm. Pharmacol.; 1979; 31:1-6
10. Botzolakis, J. E. and Augsburger, L. L.; The role of disintegrants in hard-gelatin capsules; J. Pharm. Pharmacol.; 1984; 36:77-84
11. Sanderson, I. M.; Kennerley, J. W.; Parr, G. D.; An evaluation of the relative importance of formulation and process variables using factorial design.; J. Pharm. Pharmacol.; 1984; 36:789-795
12. Özyazici, M.; Sevgi, F.; Ertan, G.; Sustained-release dosage form of nicardipine hydrochloride: Application of factorial design and effect of surfactant on release kinetics; Drug Dev. Ind. Pharm.; 1997; 23(8):761-770.
13. Carr, R. L., Evaluating flow properties of solids; Chem. Eng.; 18; 1965; p. 163-168.
14. Hausner, H. H., Friction conditions in a mass of metal powder; Int. J. powder metal; 3; 1967:7-13.
15. Cole, G. C., Hard capsules, development and technology; Ed. By Ridgway, K.; 1987; The pharmaceutical press, London, p. 61-80.
16. Doi, Y.; Mori, Y.; Urata, N.; Miziro, M.; Syoji, M.; Marubuchi, S.; Arai, H.; Histological study on healing of cryocautery induced rat gastric ulcer treated with T-593; Nippon Yakurigaku Zasshi; 1999; 113(3):167-176.
17. Kataoka, H.; Ioi, T.; Kiso, T.; Tanaka, C.; Shinkawa, R.; Kakita, T.; Shogaki, T.; Furukawa, M.; Ohtsubo, Y.; Pharmacological profiles of a new antiulcer agent, SWR-215»; Boil. Pharm. Bull.; 1997; 20(1):28-35
18. Yamamoto, O.; Okada, Y.; Okabe, S.; «Effects of a proton inhibitor on omeprazole on gastric secretion and gastric and duodenal ulcers of erosions in rats Dig. Dis and Sci.; 1984; 29 (5):394-401.
19. 1 on gastric secretion and ulcer formation in the rat; Gastroenterology; 1968; 55(4); p. 481-487.
20. Verheyen S, Blaton N, Kinget R, Van den Mooter G.; Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions; Int. J. Pharm.; 2002; 249(1-2):45-58.
21. Trapani, G.; Franco, M.; Latrofa, A.; Pantalio, M. R.; Provenzano, M. R.; Sanna, E.; Macioco, E.; Liso, G.; Physicochemical characterization and in vivo properties of zolpidem in solid dispersions with polyethylene glycol 4000 and 6000; Int. J. Pharm.; 1999; 184:121-130.
22. Pan, R. N.; Chen, J. H.; Chen, R. R. L.; Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems; Drug Dev. Ind. Pharm.; 2000; 26(9):989-994.
23. Jachowicz, R.; Nurnberg, E.; Pieszczek, B.; Kluczykowska, B.; Maciejewska, A.; Solid dispersion of ketoprofen in pellets; Int. J. Pharm.; 2000; 206:13-21.
24. Suzuki, H.; Sunada, H.; Influence of water-soluble polymers on the dissolution of nifedepine solid dispersions with combined carriers; Chem. Pharm. Bull.; 1998; 46(3):482-487.
25. Chutimaworapan, S.; Ritthidej, G. C.; Yonemochi, E.; Oguchi, T.; Yamamoto, K.; Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions; Drug Dev. Ind. Pharm.; 2000; 26(11):1141-1150.
26. Kellaway, I. W.; Najib, N. M.; Influence of hydrophilic polymer on the dissolution rate of sparingly soluble drugs. Part 1. Bulk solution viscosity effects; Int. J. pharm. Technol. Prod. Manuf.; 1983; 4:37-39.
27. Zerrouk, N.; Mennini, N.; Maestrelli, F.; Chemtob, C.; Mura, P.; Comparison of the effect of chitosan and polyvinylpyrrolidone on dissolution properties and analgesic effect of naproxen; Eur. J. Pharm. Biopharm.; 2004; 57:93-99
28. Ramakrishnan M, Kenoth R, Kamlekar RK, Chandra MS, Radhakrishnan TP, Swamy MJ; N-Myristoylethanolamine-cholesterol (1:1) complex: first evidence from differential scanning calorimetry, fast-atom-bombardment mass spectrometry and computational modeling; FEBS Lett. 2002; 531(2):343-347.